BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

Shots:

• The P-II (NCT03209973) study result involves assessing of tislelizumab (200mg, IV, q3w) as a monothx. in 70 patients with R/R to autologous stem cell transplantation (ASCT) or 2L+ r/r cHL
• The P-II study results: high anti-tumor activity in patients; ORR (87.1%); CR (62.9%); PR (24.3%); @12mos. PFS (73.8%); well tolerated; presented at 24thCongress of the European Hematology Association (EHA)
• Tislelizumab (BGB-A317) is an IgG4 anti–PD-1 mAb, minimizing the binding of FcγR on macrophages, being developed by BeiGene and Celgene for solid tumors cancer outside Asia (Ex Japan). NMPA has accepted its NDA and has granted PR designation for r/r cHL in China

Click here to read full press release/ article | Ref: Beigene | Image: Switzerland Global Enterprise